Tennessee plaintiff Major P. is suing Janssen and Bayer Pharmaceuticals for the injuries he allegedly suffered after taking their anticoagulant drug, Xarelto. Major alleges that as a direct result of the medication, he suffered severe internal bleeding that required hospital intervention.

Like many patients across the United States, Major had been prescribed Xarelto to treat his atrial fibrillation symptoms, which included stroke prevention, according to his Xarelto bleeding lawsuit. Ideally, this medication would have prevented blood-clotting in the plaintiff’s brain and allowed for a healthier and comfortable lifestyle.

Major began taking Xarelto on March 15, 2014, but he only took the blood thinner until May of the same year, when the alleged bleeding event occurred, which resulted in life-threatening injuries that required emergency medical intervention and hospitalization.

Major is filing this Xarelto lawsuit against Janssen and Bayer for failing to protect him against these injuries, claiming that the warning label did not sufficiently explain the bleeding risks. Additionally, the label failed to mention that there was no reversal agent and did not call for frequent blood monitoring.

Major argues that the companies should have included stronger precautions on Xarelto’s label and given more information about such Xarelto bleeding side effects to his doctor.

Furthermore, Major’s Xarelto uncontrollable bleeding lawsuit claims that Janssen and Bayer had the civic responsibility to warn Major and other patients of all Xarelto side effects because consumers rely on the accuracy of the given information. Major insists that he never would have used Xarelto if he had known about the possibility of bleeding injuries.

So for being allegedly responsible for manufacturing, selling, distributing, and marketing a dangerous drug, Major is suing Janssen and Bayer Pharmaceuticals. The charges include: negligence, false advertising, concealing information, and misrepresenting a product.

This Xarelto Bleeding Lawsuit is Case No. 15-cv-00032, in the U.S. District Court for the Eastern District of Tennessee, Chattanooga Division.

Overview of Xarelto Complications

Xarelto (rivaroxaban) is part of a new generation of blood thinners that is typically prescribed to patients with atrial fibrillation, who are typically at high risk for a stroke. It was approved by the U.S. Food and Drug Administration (FDA) in 2011, and was released as a joint effort by Bayer and Janssen Pharmaceuticals to be a competitor to Warfarin and the other new generation anticoagulants on the market at the time such as Pradaxa.

Pradaxa, released by Boehringer Ingelheim, had been approved a year earlier and was the first drug approved after Warfarin for the purposes of an anticoagulant.

Soon after its release, Xarelto had proven to be a marketing success for Bayer and Janssen as its sales outranked Pradaxa in profits and popularity. Unfortunately, it did not save Xarelto from its intense scrutiny from the legal community and general public after it was discovered that it may have had the same design defect as Pradaxa.

Boehringer recently settled Pradaxa lawsuits for millions of dollars after plaintiffs reported suffering uncontrollable bleeding injuries after ingesting the drug. Xarelto has been indicated to cause the same complication, which has caused a major legal movement against Bayer and Janssen.

According to the Xarelto lawsuits, Xarelto lacks a reversal agent for bleeding injuries and does not require dosage adjustments, contrasting greatly with the originally preferred anticoagulant, Warfarin. For this reason, medical experts now recommend that physicians use a different medication or method to prevent further bleeding injuries.

While the new generation anticoagulants are now being closely observed for bleeding injuries, it does not help the patients who were already injured by the drug’s side effects. Across America, thousands of patients are filing Xarelto lawsuits against Bayer and Janssen, alleging product liability charges.